1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Ishita Drugs & Industries Ltd.

Ishita Drugs & Industries Ltd.

BBSE:ISHITADR
72.75
INR
-2.25
(-3.00%)
2.36EPS
31.35P/E
221.28MMarket Cap
Ishita Drugs & Industries Ltd.
BSE:ISHITADR
(Bombay Stock Exchange)

Recent

price

72.75

P/E

ratio

31.35

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
29.76
17.25
39.34
24.53
23.3
21.87
19.53
22.65
30.39
49.6
46.65
47.12
40.37
50.79
50.15
49.03
41.45
Revenue per Share
1.31
0.69
1.4
0.68
0.74
0.46
0.61
0.83
1.18
1.83
2.77
2.69
1.93
2.5
2.9
2.6
2.36
Basic EPS, GAAP
- -
- -
-1.81
1.47
0.2
0.84
1.58
1.39
1.74
3.45
-2.27
10.23
-10.14
7
-12.78
6.92
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
16.95
17.63
18.38
18.83
19.44
20.27
21.45
23.28
26.05
28.75
30.68
33.18
36.08
38.69
- -
Book Value per Share
- -
- -
16.95
17.63
18.38
18.83
19.44
20.27
21.45
23.28
26.05
28.75
30.68
33.18
36.08
38.69
- -
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
88
52
118
73
70
65
58
68
91
148
139
141
121
152
150
147
124
Sales/Revenue/Turnover
6.88
6.51
3.83
4.29
2.4
1.85
3.78
4.67
3.96
3.95
5.53
6.82
5.24
5.25
5.95
4.54
4.96
Operating Margin (%)
1
1
1
1
2
2
1
1
2
2
1
1
1
1
1
1
1
Depreciation Expense
4
2
4
2
2
1
2
2
4
5
8
8
6
7
9
8
7
Net Income, GAAP
33.53
32.85
31.58
32.96
23.13
28.76
29.01
23.33
24.05
23.31
21.27
22.82
25.92
24.18
24.85
27.92
28.85
Effective Tax Rate (%)
4.4
4
3.55
2.78
3.18
2.1
3.12
3.66
3.87
3.69
5.95
5.71
4.78
4.93
5.79
5.31
5.69
Profit Margin (%)
- -
- -
39
39
41
44
47
48
51
57
66
74
80
88
96
86
- -
Working Capital
- -
- -
1
1
- -
- -
- -
1
1
- -
- -
- -
- -
- -
1
- -
- -
LT Debt
- -
- -
51
53
55
56
58
61
64
70
78
86
92
99
108
116
- -
Total Equity
- -
- -
- -
4
2.35
1.39
2.48
3.96
4.16
6.34
7.84
8.75
4.9
5.96
5.36
3.58
- -
Return on Invested Capital (%)
- -
- -
- -
4.13
4.32
2.41
3.08
5.32
6.08
8.12
11.2
9.84
6.45
7.94
7.27
6.11
- -
Return on Capital (%)
- -
- -
- -
3.95
4.12
2.47
3.19
4.17
5.64
8.18
11.25
9.82
6.5
7.84
8.38
6.96
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
239
207
221

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
95
- -
Cash, Cash Equivalents & STI
- -
68
- -
Accounts Receivable, Net
- -
10
- -
Inventories
- -
9
- -
Total Current Liabilities
- -
10
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.49%
8.24%
7.22%
Free Cash Flow
-132.1%
-270.94%
-154.13%
Net Income, GAAP
22.2%
0.81%
-10.32%
Sales/Revenue/Turnover
10.57%
1.8%
-2.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
30
33
41
46
150
2026
54
31
31
31
147
2027
31
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.49
0.65
0.8
0.96
2.9
2026
1.01
0.48
0.52
0.59
2.6
2027
0.77
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Ishita Drugs and Industries Limited (ISHITADR.BO), the flagship company of the Ishita Group, manufactures and sells active pharmaceutical ingredients (APIs), drug intermediates, fine chemicals, and excipients primarily in India and exports to over 25 countries. Incorporated in 1992 and headquartered near Ahmedabad, Gujarat, the company produces a range of products including sulfa drugs and sulfonamides such as sulfanilamide and sulfathiazole; vitamins and derivatives like nicotinic acid, niacin, nicotinamide, and methyl nicotinate; excipients such as citric acid monohydrate, maize starch, sodium starch glycolate (Pumojel brand from potato and maize starch), sodium chloride, and potassium chloride; as well as pyrazinamide, fluoroquinolones, antibiotics, anthelmintics, iodides, citrates, and other fine chemicals like hexa methyl disilazane, pyridine hydrobromide, ethyl 3a benzoyl acrylate, and 4,4' dimethyl benzil. Its manufacturing facilities, designed to GMP standards and ISO 9001:2015 certified, are located in Gujarat at Vasana-Iyava near Sanand (Ahmedabad district), Surendranagar, and Mehsana for APIs, intermediates, and formulations, serving leading pharmaceutical companies with audited quality compliance. Recent developments include an ongoing manufacturing facility upgrade to comply with Revised Schedule M regulations, with civil construction expenditures of approximately Rs 50 lakhs as of September 2025 amid monsoon delays; approval of related party transactions with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited; reappointment of independent director Arvind Vilasrao Sapkal for a second five-year term; and a board proposal to pursue new business opportunities within its memorandum of association, alongside mixed quarterly financial results showing Q2 FY2026 revenue growth but net profit decline.